GHK (without copper) vs Ipamorelin

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

GHK (without copper)Ipamorelin
CategoryPeptidesPeptides
Standard DoseResearch indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily.Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.
TimingTopical application morning and evening. Injectable in evening.Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.
Cycle DurationTopical use can be ongoing indefinitely. Injectable cycles 8-12 weeks.12-24 week cycles with 4-8 week breaks.
Evidence Levelmoderate_humanmoderate_human

Mechanism

GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide found in human plasma, saliva, and urine that has an extremely high affinity for copper(II) ions. Even without exogenously complexed copper, GHK rapidly chelates available copper in biological systems, making copper-free GHK functionally similar to GHK-Cu in vivo. The peptide stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinase activity, resets gene expression patterns toward a healthier state (affecting 31.2% of human genes), and activates wound healing cascades.

Standard Dosing

Research indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily.

Timing

Topical application morning and evening. Injectable in evening.

Cycle Duration

Topical use can be ongoing indefinitely. Injectable cycles 8-12 weeks.

Side Effects

  • Mild skin irritation (topical)
  • Injection site reactions

Contraindications

  • Wilson's disease
  • Pregnancy and breastfeeding

Best Stacking Partners

GHK-CuBPC-157Epitalon
B

Ipamorelin

Peptides

Mechanism

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as the first selective growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) agonist. Unlike other GHRPs, it selectively stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or aldosterone — even at doses 200-fold above the ED50 for GH release. This selectivity profile is comparable to GHRH itself but operates through the distinct ghrelin receptor on pituitary somatotrophs.

Standard Dosing

Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.

Cycle Duration

12-24 week cycles with 4-8 week breaks.

Side Effects

  • Head rush post-injection
  • Mild hunger increase (less than GHRP-6)
  • Water retention (mild)
  • Tingling in extremities
  • Injection site irritation

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)BPC-157TB-500

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →